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resumo As doenças inflamatórias são a principal causa de morbilidade e 
mortalidade em todo o mundo e representam um grande desafio na área das 
ciências biomédicas. Sendo assim, o desenvolvimento de terapias é essencial e, 
para tal, uma compreensão do funcionamento do sistema imune do hospedeiro é 
fundamental. 
A ativação do sistema complemento representa o passo inicial para o 
desenvolvimento de uma resposta imune-infamatória protetiva contra o dano. 
Porém, uma ativação inapropriada poderá danificar o tecido do hospedeiro, sendo 
potencialmente destrutivo, podendo causar diversas doenças. 
A proteína solúvel responsável pela inibição do sistema complemento, 
C4b-binding protein (C4BP), atua tanto na regulação da via clássica como na de 
lectina do sistema complemento, modificando a atividade da C3 convertase e 
prevenindo, assim, a expressão exagerada deste sistema e, consequentemente, o 
dano tecidual no hospedeiro.  A C4BP é uma grande glicoproteína plasmática 
oligomérica, composta por sete cadeias α idênticas e uma única cadeia β, que 
forma três oligómeros plasmáticos devido a diferentes composições de 
subunidades. A isoforma C4BP sem a cadeia β, C4BP (β-), parece apresentar uma 
função direta na modulação de respostas imunes adaptativas. Estudos recentes no 
laboratório demonstraram que a C4BP (β-) é capaz de promover um perfil 
tolerogénico e anti-inflamatório em células dendríticas derivadas de monócitos.  
Os macrófagos são células amplamente distribuídas do sistema imune 
inato que apresentam uma função central na defesa do organismo contra 
patógenos invasores e no mantimento da imune homeostase, contribuindo para a 
inflamação e promovendo a cura de feridas e reparação de tecidos. São células 
dinâmicas que maturam sob a influência de sinais provenientes do 
microambiente.  
 
  
   
 
Neste estudo, monócitos de sangue periférico humano foram 
diferenciados em macrófagos (M0) e, posteriormente, polarizados a fenótipos M1 
e M2, utilizando LPS/IFN-γ, e IL-4, respetivamente. M1 e M2 foram 
identificados por citometria de fluxo como CD80+ CD64+ e CD11b+ CD209+, 
respetivamente.  
A atividade endocítica e fagocítica foi também investigada dado que os 
macrófagos são células altamente fagocitárias. Quando os macrófagos foram 
maturados ao fenótipo M1, uma diminuição da capacidade endocítica foi 
observada, comparando com as células não polarizadas (M0). No entanto, quando 
os macrófagos foram polarizados ao fenótipo M2, não foi evidente uma 
diminuição da expressão da atividade endocítica, comparando com M0, 
evidenciando, assim, que M2 são células com elevada capacidade endocitária. 
Além disto, macrófagos M2 também demonstraram uma capacidade fagocitária 
superior a macrófagos M1. E concluindo, a proteína C4BP (β-) reduziu a 
atividade endocítica dos macrófagos, embora não tenha apresentado qualquer 
efeito na atividade fagocítica. 
Alterações no fenótipo e função dos macrófagos pode estar associado 
com uma variedade de doenças autoimunes, incluindo o lúpus eritematoso 
sistémico. Esta enfermidade é caracterizada por várias manifestações desde a pele 
e lesões nas mucosas a danos severos nos rins e no sistema nervoso central. 
Assim, marcadores da doença mais eficazes, risco, atividade da doença e 
gravidade dos danos nos órgãos poderão facilitar o diagnóstico prévio e orientar 
o paciente para uma terapia adequada; dado que os tratamentos atuais não são 
totalmente eficientes. Por esta razão, o desenvolvimento de novas estratégias é 
fundamental, e a atividade anti-inflamatória e imunomodeladora da C4BP (β-) 
poderá representar uma opção terapêutica para esta doença autoimune. 
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abstract Inflammatory diseases are the leading cause of morbidity and mortality 
worldwide and are a major challenge for the biomedical sciences. The 
development of therapeutics is essential and this requires an understanding of the 
host immune system.  
The activation of the complement system represents the initial step in the 
protective immune-inflammatory response against damage. Nevertheless, an 
inappropriate activation may also damage the host tissue, being potentially 
destructive and causing several diseases. 
The soluble complement inhibitor C4b-binding protein (C4BP) acts in the 
regulation of the classical and lectin pathways of the complement system, 
modifying the activity of the C3 convertase, and preventing complement over 
activation and host tissue damage. C4BP is a large oligomeric plasma 
glycoprotein, composed by seven identical α-chains and a single β-chain, which 
forms three plasma oligomers with different subunit composition. The C4BP 
isoform without the β-chain, C4BP (β-) seems to play a direct role in the 
modulation of adaptive immune responses. Recent studies in the lab 
demonstrated that C4BP (β-) is able to promote a tolerogenic and anti-
inflammatory profile on monocyte-derived dendritic cells. 
Macrophages are widely distributed innate immune cells that play central 
roles in host defense against invading pathogens and in maintaining the immune 
homeostasis, contributing to inflammation, and promoting wound healing and 
tissue repair. They are dynamic cells that mature under the influence of signals 
from the local microenvironment.  
 
 
  
 
In this study, human peripheral blood monocytes were differentiated into 
uncommitted macrophages (M0) and then polarized to M1 and M2 phenotypes 
using LPS and IFN-γ, and IL-4, respectively. M1 and M2 were identified by flow 
cytometry as CD80+ CD64+ and CD11b+ CD209+, respectively.  
The endocytic and phagocytic activity was also investigated, since 
macrophages are highly phagocytic cells. When macrophages were matured to 
M1 phenotype, a downregulation of the endocytic activity was observed, 
compared to the unpolarized cells. In contrast, when macrophages were polarized 
to M2 phenotype, no downregulation of endocytic activity compared with M0 
was evidenced, showing that M2 are highly endocytic cells. Moreover, M2 
macrophages showed a higher phagocytic activity than M1 macrophages. Finally, 
C4BP (β-) reduced the endocytic activity of macrophages, although did not have 
any effect on its phagocytic activity.  
Alterations in the phenotype and function of macrophages can be 
associated with a variety of autoimmune disorders, including systemic lupus 
erythematosus. This disorder is characterized by several manifestations from the 
skin to mucosal lesions, to severe damage in the kidneys and in the central 
nervous system. More effective markers of the disease, risk, disease activity; 
severity of organ damage and of the outcomes would facilitate earlier diagnosis 
and guide appropriately targeted therapy; since the actual treatments are not fully 
effective. For this reason, the development of new strategies is fundamental, and 
the anti-inflammatory and immunomodulatory activity of C4BP (β-) can 
represent an effective therapeutic option to this autoimmune disease. 
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Chapter 1 
Introduction 
 
1.1. Innate immunity 
 
Mammalian hosts can be colonized by endogenous microorganisms in the skin, intestine 
and upper respiratory tract, but other niches, such as the internal organs and the lower 
respiratory tract, are usually kept sterile. The effect of microbial colonization can be positive, 
providing a range of benefits to the host, like the case of intestinal bacteria, but, in other cases, 
the microbial colonization can be damaging to the host. In this last case, the colonizing bacteria 
is referred to as a pathogen [1].  
The immune system is a biological mechanism that has the main function of supporting 
the organism homeostasis, there why fighting aggressions from different sources. This 
mechanism confers the ability to resist, neutralize or eliminate pathogens that would be capable 
of destroying it [2]. The damaging effects of microbial infections led to the evolution of a 
variety of host-defense mechanisms, triggering an immune response that can be classified into 
innate and adaptive immunity. 
 Innate immunity constitutes the first line of host defense against pathogen invasion and 
spread in the early phase of infection, is present in all plants and animals [3]. This first line of 
defense is composed of a variety of myeloid and lymphoid cells that present a more rapid and 
non-specific defense response. These cells are genetically programmed to detect invariant 
molecular patterns of invading microbes, recognizing invading pathogens through germline-
encoded pattern recognition receptors (PRR) [4].  
It was thought that the innate immune response does not present an immunological 
memory, classified like non-self; phagocytosing and digesting the invading pathogens in a non-
specific way [5, 6]. However, some recent studies defend that the innate immune response 
against invading microbes initiates with a recognition of commonly found components on the 
microorganisms, that are not usually present in the host, referred as pathogen-associated 
molecular patterns (PAMPs) [7]. Nevertheless, they are present on both pathogenic and  non-
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pathogenic microorganisms, and the PRRs themselves are not capable of distinguishing 
between them because the ligands of the receptors are not unique to pathogens. Even that, 
PAMPs are well suited to innate immune recognition for several reasons, being invariant 
between microorganisms of a given class. PAMPs are products of pathways that are exclusive 
to microorganisms, which allows a discrimination between self and non-self molecules and they 
also present essential roles in microbial physiology [1]. 
The immune system uses the microbial sensing pathways to maintain host-microbial 
homeostasis and to induce anti-microbial defense mechanisms [8]. The distinct PRRs can be 
categorized into secreted, transmembrane and cytosolic. Secreted PRRs have the capacity to 
bind to the microbial cell surface, activating the classical and lectin pathways of the 
complement system, and to opsonize pathogens for posterior phagocytosis by macrophages. 
The transmembrane PRRs class include the Toll-like receptors (TLRs) family, that are 
responsible for the cell innate immune recognition, identifying viral nucleic acids and several 
bacterial products. Even that, the TLR activation does not involve an infected cell [8].  
This type of immunity is represented by a physical, biological and chemical barrier, 
fundamental to stop the spreading of infectious agents [3, 9]. The main effector cells, the 
antigen-presenting cells (APC) such as macrophages, neutrophils and dendritic cells (DC), 
express TLRs on their cell surface [6]. When the PAMPs bind and activate the TLRs on the cell 
surface, an inflammatory and anti-microbial response is initiated. TLRs activate tissue-resident 
macrophages to produce pro-inflammatory cytokines, among them the tumor-necrosis factor 
(TNF) and interleukin (IL)-6, that are responsible for the local and systemic inflammatory 
response coordination.  
TNF activates the local endothelium to induce vasodilation and raise the blood vessel 
permeability, allowing the passage of serum proteins and leukocytes to the site of infection. In 
turn, an increase of IL-6 activates hepatocytes to produce proteins such as collectins, ficolins 
and pentraxins. The main functions of these proteins are opsonizing microbial cells for 
phagocytosis by macrophages and neutrophils and activating the complement system [1]. Thus, 
with this antigen presentation, activation of complement system proteins and production of pro-
inflammatory cytokines and chemokines, leads to T cell activation [6,8]. With this activation 
the adaptive immunity initiates, proving that the two types of immunity are essentially 
connected [7].  
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1.2. Adaptive immunity 
 
The adaptive immunity is present only in vertebrate animals and allows a stronger 
immune response, dependent on the production of specialized cells that are highly efficient in 
pathogen elimination, mediated by antigen receptors. The specialized cells of this type of 
immunity are a special type of leukocytes, derived from the bone marrow, called lymphocytes. 
These can be divided into T and B cells, involved in the cell-mediated immune response and in 
the humoral immune response, respectively. These cell types can work together, and with the 
support from other types of cells they assure an effective adaptive immunity [10].  
In the first stage of evolution, the lymphocyte progenitor gives origin to an immature T 
cell, becoming a specialized cell. Next, somatic assembly allows T cells express a diverse 
repertoire of functional antigen receptors with random but narrow specificities on their cell 
surface, responsible for the cell survival [1, 11]. In a later stage, the antigen receptor expressed 
by the T-cells, develop the ability to interact with antigen-presenting molecules [11]. Antigen 
receptors are clonally distributed on the T and B lymphocytes. In other words, each lymphocyte 
express antigen receptors with a single specificity, which allows a clonal selection of pathogen-
specific receptors, being responsible for an immunologic memory, characteristic of adaptive 
immunity [1]. 
Then, the surviving cells migrate to the peripheral lymphoid tissues through the blood-
stream, where they experience clonal expansion and differentiation, becoming effector T 
lymphocytes or antibody-producing plasma cells [10]. In T and B cells, the expression of a 
functional antigen receptor at the cell surface is fundamental for survival and progression to 
successive stages in the differentiation pathway [11], evidencing that there is a fundamental 
connection between innate and adaptive immunity. The magnitude and quality of the adaptive 
immune response are dependent on signals derived from the innate response to infection. 
 
1.3. Development of hematopoietic stem cells  
 
Hematopoietic stem cells (HSCs), produced in the bone marrow, have the unique ability 
to generate all the different mature blood cell types and they can be separated into three lineages. 
Vertebrates are constituted by several highly specialized cell types involved in gas transport, 
such as red blood cells (RBCs) or erythrocytes. In mammals, erythrocytes and thrombocytes 
are small, but highly specialized cells without a nucleus. The myelocytes, also derived from 
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common myeloid progenitors, which include the white blood cells (WBCs) or leukocytes, 
exhibit numerous morphological and functional classes, being possible to distinguish 
granulocytes (polymorphonuclear leukocytes) from mononuclear leukocytes (also called 
agranulocytes), once they present functional and physical characteristics. Derived from 
common lymphoid progenitors, the lymphocytes are responsible for the immune response and 
tissue repair, and the lymphoid lineage is mainly composed of T-cells and B-cells (Figure 1) 
[12]. 
Granulocytes such as basophils, neutrophils, eosinophils and mast cells, have a 
segmented nucleus and are packed with little granules, also known as lysosomes. These 
organules are filled with a diversity of enzymes involved in the attack and digestion of bacteria 
and other pathogens. Conversely, agranulocytes are divided into two groups: monocytes and 
lymphocytes. In humans, monocytes represent about 10% of the circulating leukocytes and, as 
phagocytes, they invade the tissue at sites of damage and infection. Once in the tissue, they 
undergo further differentiation becoming macrophages (Figure 1) [12].  
Monocytes represent immune effector cells, equipped with chemokine receptors and 
adhesion receptors that mediate migration from blood to tissues during infection. They produce 
inflammatory cytokines and take up cells and toxic molecules and they can also be 
differentiated into inflammatory DCs or macrophages during inflammation. Migration to 
tissues and differentiation to inflammatory DCs and macrophages are likely determined by the 
inflammatory milieu and pathogen-associated pattern-recognition receptors [13]. 
Dendritic cells are specialized antigen processing and antigen-presenting cells, since they 
can take up a diverse array of antigens and present them to T cells as peptides. These cells are 
equipped with high phagocytic activity as immature cells and high cytokine-producing capacity 
as mature cells. DCs are highly migratory cells that can move from tissues to the T cell and B 
cell zones of lymphoid organs via afferent lymphatics and high endothelial venules. These cells 
regulate T cell responses both in the steady state and during infection [14].  
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Figure 1. Development of the hematopoietic stem cell to mature and highly specialized cell types. Derived from 
a common myeloid progenitor, the erythrocytes are responsible for gas transport, while the myelocytes are 
involved in  innate immunity, adaptive immunity, and blood clotting, being distinguished between granulocytes 
and mononuclear leukocytes (agranulocytes). Derived from common lymphoid progenitors, the lymphocytes are 
responsible for the immune response and tissue repair. The lymphoid lineage is mainly composed of T-cells and B-
cells. 
 
1.4. Monocyte-derived macrophages  
 
The most abundant leukocyte type observed, the macrophages are derived from 
circulating monocytes that differentiate when they leave the blood vessels for entry into tissue, 
where they can, afterward, be activated by an extensive array of microbial and self antigens [15, 
16]. Macrophages evolved and respond first by sensing pathogens or damage, and contribute to 
stopping inflammation, promoting wound healing and tissue repair. They play a central role in 
host defense against invading pathogens, maintaining immunological homeostasis from simple 
multicellular animals to humans [5, 17], is widely distributed.  
The macrophages express a variety of different receptors and present a high plasticity, 
being capable of interacting with several stimuli such as cytokines, and also integrate multiple 
signals from the tissue environment, responding to these by shifting their phenotype, 
metabolism and function [15, 18]. To combat the aggression and, in response to cytokines or 
microbial products, the monocytes may differentiate into macrophages. Changing their 
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phenotype, the macrophages experience polarization, resolving the tissue damage. The 
hallmark function of the M0/M1/M2 system is phagocytosis and subsequent antigen 
presentation. Phagocytosis triggers the activation of receptors which, in turn, transmit signals 
to the cell interior to initiate the response. Following digestion of the target, M1/M2 
macrophages present target-derived antigens to relevant T-cells, responsible for the production 
of cytokines that connect to TLRs [17, 19].  
This shift is possible because the macrophages are dynamic cells with an exclusive ability 
to be activated in two different states. Each of these states present a different type of response: 
the classically activated macrophages (M1), responsible for inhibiting or killing non-functional 
cells or pathogens, or the alternatively activated (M2), in charge of sustaining the organism 
homeostasis by helping tissue repair, replacing lost or old cells, and promoting anti-parasitic 
and anti-allergic reactions [16, 17]. This differentiation is based on surface receptors, gene 
signatures, and secretion of inflammatory mediators [20]. 
From human peripheral blood, monocytes can be differentiated into uncommitted 
macrophages (M0) and then polarized to M1 and M2 phenotypes by potent hematopoietic 
growth factors such as granulocyte-macrophage colony stimulating factor (GM-CSF) and 
macrophage stimulating factor (M-CSF), respectively [20]. On one hand, M1 is usually induced 
by microbial stimuli, such as lipopolysaccharide (LPS), and pro-inflammatory cytokines, as 
interferon-ᵞ (IFN-ᵞ) and tumor necrosis factor-α (TNF-α), promoting a pro-inflammatory 
response responsible for extracellular matrix degradation and tissue injury. On the other hand, 
M2 macrophages are stimulated by interleukin (IL)-4 and/or IL-13, producing transforming 
growth factor beta (TGF-β) and IL-10, that are usually involved in inflammatory response 
resolution and wound healing, promoting extracellular matrix construction and cell 
proliferation with a characteristic anti-inflammatory response [18].  
After the M0 macrophages are matured to M1 and M2, with activation factors (IFN-ᵞ, 
TNF-α, LPS or IL-4), the polarized macrophages express surface markers that allow to 
distinguishing between their different states (M0, M1, and M2). CD64 and CD80 are 
characteristic markers produced by M1 macrophages polarized by LPS and IFN-ᵞ, and M2 
macrophages express CD209 and CD11b markers on their cell surface [20]. 
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1.5. Complement system 
 
Not only the cell-based innate immune system, but also the soluble complement (C) 
system play essential roles in host defense and inflammation. Primarily described as a 
complement to humoral immunity for the simple elimination of bacteria by heat stable 
antibodies, now it is recognized as a central component of innate immunity, recognizing and 
initiating a protective response to kill deleterious invaders, resulting in opsonization of 
pathogens for their further removal by phagocytosis [21].  
The complement system is an evolutionarily conserved mechanism driving the initiation 
of inflammation and coordinating various events during this process. Thus, it is a key 
component of the innate immune system connecting innate and adaptive immunity [22]. 
Unfortunately, inappropriate complement activation and complement deficiencies can be 
deleterious, causing severe tissue damage and leading to pathology, producing a variety of 
inflammatory and autoimmune diseases like systemic lupus erythematosus [21]. 
This system is characterized by a complex network of cell surface receptors and more 
than 30 serum proteins that are present as soluble proteins in the blood or as membrane-
associated proteins [21, 23]. Moreover, these proteins hold also additional functions like the 
development of B and T cell responses, proving that the complement also plays an important 
role in the adaptive immunity [24].  
The complement system, as the TLRs, can be activated by pattern recognition 
receptors, which have the ability to distinguish between self and non-self antigens based on 
PAMPs. The serum proteins, in addition to specific antibodies, confirm the recognition 
structures involved in complement activation [24]. The complement activating PRR include 
mannose binding lectin (MBL), ficolins, C-reactive protein, C1q and natural IgM. These PRRs 
allow a rapid initiation and a high efficiency of the complement system cascade as an early 
immune response to inflammation [23]. 
The complement system can be activated by three different pathways: classical, lectin and 
alternative. These three pathways differ according to the nature of recognition, but all share a 
common step of activating the central component C3, which is the most abundant complement 
protein in the blood [21, 24].  
The classical pathway is initiated by antibodies that are produced during the humoral 
response, generated when occurs an inflammatory reaction. In the classical pathway, the 
binding of C1q to antigen-antibody complexes initiates a proteolytic cleavage of various 
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complement components. The lectin pathway starts with the recognition and binding of PAMPs 
by lectin proteins, like MBL. That binding to pathogens induces conformational changes. C1q 
and MBL are structurally identical molecules, and both pathways require C2 and C4 
complement components for the generation of the C3 convertase. The alternative pathway 
differs significantly from the other two because is initiated by a spontaneous C3 hydrolysis. 
This last one, forms a complex with factor B, followed by a cleavage of the created complex 
by factor D [21, 23]. 
The three pathways of complement activation converge on the formation of C3 
convertases that are responsible for the cleavage of C3 in C3a and C3b. C3b binds covalently 
to surfaces and as opsosin helps in the target cells phagocytosis and also contributes to the 
complement activation with the formation of C5 convertase, that splits C5 in C5a and C5b. C3a, 
C4a, and C5a complement effectors present a multitude of effects in inflammatory responses, 
acting as chemoattractants for phagocytes cells, such as neutrophils and monocytes, to sites of 
injury or inflammation [21, 23]. They act as vasodilators and induce smooth muscle contraction 
and C5b initiates the formation of C5b-9 terminal complement complex (Figure 2), which is 
incorporated into bacterial cell walls, causing pores on the target cells and inducing their lysis 
[23, 25]. 
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Figure 2. Complement activation though the classical (1), lectin (2), or alternative (3) pathways that converge at the 
central component of the complement system, C3. C3 and C5 can be cleaved by proteolytic enzymes that are released 
from leukocytes. (1) The binding of C1 complex to antigen-antibody complexes initiates proteolytic cleavage of the 
complement components. C1s first cleaves C4, which binds to the bacterial surface, then cleaves C2, leading to the 
formation of C4b2a complex (the C3 convertase of the classical pathway). (2) The lectin pathway begins by binding 
of the complex MBL to a bacterial wall, leading to the formation of C3 convertase C4b2a. (3) The alternative way 
is initiated by spontaneous hydrolysis of C3. The formed complex has the capacity to cleave C3 to C3a and C3b. 
C3b contributes to the formation of the C5 convertase, which cleaves C5 to C5a and C5b. C3a, C5a and C5b-9 
complex are complement effectors that contribute to inflammation. C5ab-9 complex induces bacteria lysis. 
(Adapted from [23]) 
 
The elimination of invading pathogens by the complement system may also damage the 
host issue due to an inappropriate complement activation or complement deficiency, being 
potentially destructive to the organisms and causing several diseases. Given the multitude of 
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complement effects, there are mechanisms that prevent its action, limiting the complement 
activation. This control can be accomplished by inhibition of the C3 convertase activity by 
soluble or membrane-associated regulatory proteins. These work as cofactors for the proteolysis 
of the activated proteins C3b and C4b. C4b-binding protein (C4BP) and Factor H (FH) are 
examples of these proteins [26]. 
 
1.6. C4b-binding protein (C4BP) 
 
C4BP is the major soluble inhibitor acting on the C3 convertase, either by increasing the 
dissociation of the enzyme complex, accelerating the decay of the classical and lectin pathway 
C3 convertase or by being a cofactor in the proteolytic degradation of C4b. The human plasma 
protein Factor H binds to the C3b inhibiting his formation and accelerating the decay of the 
alternative pathway C3 convertase. FH can also act as a cofactor in the proteolytic degradation 
of C3b, interfering with the complement regulation [25, 27].  
C4b-binding protein is a large oligomeric plasma glycoprotein of 570 kDa that is 
primarily synthesized in the liver and secreted into the circulation in three main isoforms, which 
differ in α and β-chains combinations. The major isoform, C4BP (β+), which constitutes 75-
80% of C4BP in plasma, is composed of seven identical α-chains of 70 kDa each and a single 
β-chain of 40 kDa (α7β1). The C-terminal extension of each chain contains two cysteine 
residues, allowing the different chains to be linked by disulphide bonds, and an amphipathic α-
helix region, which is compulsory for intracellular polymerization of the C4BP, resulting in a 
spider or octopus-like structure, with the seven α-chains forming extended tentacles (Figure 3-
A) [26, 27].   
The α- and β-chains of C4BP are composed of eight and three domains termed short 
consensus repeats (SCRs) or complement control protein (CCP), respectively, each one 
containing 60 amino acid residues [26, 27]. Binding C4b is a prerequisite for the cofactor 
activity of C4BP, and the CCP1-3 region of the α-chain presents a binding site for C4b, based 
on ionic-electrostatic interactions between amino acids from both molecules, promoting the 
cleavage of C4b molecules and the decay of the classical pathway C3-convertase. The β-chain 
presents a high-affinity binding site for the anticoagulant vitamin K-dependent protein S (ProS) 
and all the β-chains of C4BP in plasma circulate in complex with protein S (Figure 3-A), which 
provides C4BP the ability to bind negatively to phospholipids present in cell membranes [27]. 
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Two more isoforms of C4BP are known besides the major circulating C4BP (β+) isoform, 
C4BP α7β1. The minor circulating C4BP (β-) isoform, with seven identical α-chains and without 
the β-chain, also recognized as C4BP (β-) or C4BP α7β0, is inducible under inflammatory 
conditions (Figure 3-B). The recombinant C4BP isoform with six α-chains and without the β-
chain, identified as recC4BP (β-) or C4BP α6β0, is produced in vitro (Figure 3-C). However, 
during acute-phase conditions, C4BP (β-) becomes the major isoform in plasma, as a 
consequence of the differential regulation of the genes encoding the α and β chains by 
proinflammatory cytokines [26].  
 
 
Figure 3. Schematic structure of the main C4BP isoforms used in this study. (A) The major circulating C4BP (β+) 
isoform (C4BP α7β1), bound to ProS. (B) The minor circulating C4BP (β-) isoform (C4BP α7β0), inducible under 
proinflammatory conditions and, (C) a recombinant protein (recC4BP (β-) or C4BP α6β0) produced in vitro from 
a genetically engineered eukaryotic cell line. 
 
Recently, it was reported that the administration of human C4BP was able to inhibit the 
development of autoimmune arthritis in mice. This suggests that other mechanisms might be 
involved in the anti-inflammatory activity of C4BP. It was also demonstrated that the C4BP (β-
) isoform is capable of inducing a tolerogenic state in stimulated dendritic cells with phenotypic, 
morphologic and functional characteristics analogous to immature DC (iDC), and that the CCP6 
domain is necessary for the C4BP (β-) tolerogenic activity in these cells. [26]. 
Major pathologies arising from a deficient complement activation are autoimmune 
disorders. These occur when a specific adaptive response is directed against self-antigens and, 
as a result, an immune response develops and leads to chronic inflammation and injury to the 
host tissues [23]. Systemic Lupus Erythematosus (SLE) is one of these autoimmune disorders, 
often found associated with the deficiency in C1q of the classical complement activation 
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pathway [21]. Anomalies in the macrophages phenotype and function are also related to 
autoimmune disease. Some theories affirm that macrophages involved in SLE present a 
deficient phagocytic function, causing an abnormal accumulation of apoptotic products that 
gives place to autoimmune disorders [28]. 
 
1.7. Systemic Lupus Erythematosus 
 
Systemic Lupus Erythematosus is a multi-organ chronic autoimmune disorder 
characterized by several clinical manifestations from the skin and mucosal lesions to severe 
injuries in the central nervous system, kidneys, and heart among other organs. The pathogenesis 
and precise etiology, such as the mechanisms underlying many other disease manifestations, 
and the most effective therapeutic options remain unknown. Nevertheless, some genetic and 
environmental factors, like UV radiation, have been implicated as disease expression 
contributors [29, 30].  
SLE predominantly affects women with ages ranging between 18 to 65 years old, 
especially in reproductive age. In most studies, 90% or more of patients are women and it is 
estimated that 200 women per 100 000 express cases of lupus [31], and woman with African 
American or Hispanic American heritage have 3 to 4 times more risk of developing this disease 
than Caucasians. SLE is usually associated with periods of illness followed by periods of 
remission, and the diagnosis of SLE is based on clinical criteria, including fever, skin rashes, 
photosensitivity, serositis, glomerulonephritis, hematological and neurological disorders [29]. 
The presence of a high quantity of antibodies against nuclear compounds (antinuclear 
antibodies), elevated circulating immune complexes and complement consumption, causing 
damage to cells and tissues, are the main characteristics of the disease [30]. 
The humoral immune response is being used as a marker of disease activity and the 
double-stranded (ds) DNA is the main target. Antibody production directed against chromatin 
components, such as dsDNA, nucleosomes, and histones, are a hallmark of SLE pathogenesis. 
DNA-histone complexes (nucleosomes) are released in high amounts into circulation in SLE 
patients, and these nucleosomes are targets of anti-dsDNA autoantibodies [30]. Therefore, 
despite being unspecific, anti-dsDNA antibody serum levels have been correlated with disease 
activity and are clinically used as predictive markers. The development of autoantibodies 
reflects a loss of B- or T-cell tolerance, which possibly result from a combination of genetic 
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predisposition, persistent inflammatory responses, and abnormal handling of apoptotic material 
and immune complexes, abnormal presentation of self-antigens among other events [29]. 
Cell death is the most likely phenomenon for supplying autoantigens, and there are two 
main forms of cells dead, apoptosis and necrosis. When cells die through one of these forms, 
they must be quickly removed from tissues in order to prevent further inflammation and 
damage. A highly efficient scavenger system, including macrophages, polymorphonuclear 
cells, and immature dendritic cells, assure a quick elimination of apoptotic and necrotic cell 
material. An identification of markers of activity and damage, characterization of key regulatory 
circuits, identification of suppressors and activators and, in definitive, a deep understanding of 
the autoimmune pathophysiology, may allow a better understanding, treatment, and prevention 
of SLE [29].  
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Motivation 
 
Some studies confirm that, annually, around 200 women per 100 000 express lupus 
manifestations. SLE presents a high incidence and prevalence rates in women, that most often 
strikes reproductive-age women, being a relevant disease considered a matter of public health. 
The development of clinical instruments for the assessment of disease activity and disease 
damage is fundamental in SLE research. Significant advances were made in the past 2 decades 
in the understanding of the genetic predisposition to disease occurrence and the underlying 
pathophysiological mechanisms accounting for the inflammatory process and the irreversible 
organ damage that may result over time. 
The minor circulating C4BP (β-) isoform was recently capable of inducing a tolerogenic 
state in stimulated dendritic cells with phenotypic, morphologic and functional characteristics 
analogous to immature DC (iDC), evidencing that the C4BP α7β0 isoform could be used as an 
anti-inflammatory and immunomodulatory agent in autoimmune diseases. Nevertheless, a 
complete understanding of C4BP (β-) function and mechanism of action should be fully 
elucidated for, in a near future, the C4BP (β-) administration in the correct dosage, be safe and 
efficient for use in pre-clinical models and patients. 
 
 
Hypothesis and objectives 
 
Recent studies, performed in vitro, unveil the capacity of the C4BP (β-) isoform or C4BP 
α7β0, to modulate the behavior of dendritic cells [26]. The plasma-purified and recombinant 
C4BP (β-) abolished the proinflammatory phenotype of human monocyte-derived dendritic 
cells stimulated with LPS, inducing a semi mature, tolerogenic phenotype on these cells. This 
resulted in a DC surface expression pattern marked by a decrease of the maturation marker 
CD83 and reduction of the costimulatory molecules CD80 and CD86. On the other hand, a 
significant diminution in pro-inflammatory cytokines production, such as IL-12, TNF-α and 
IFN-γ, and a preferential production of anti-inflammatory cytokines, like IL-10 and TGF-β was 
evident [26].Therefore, both DC, previously treated with C4BP (β-), and the minor circulating 
C4BP (β-) isoform on its own could be used as anti-inflammatory and immunomodulatory 
agents in autoimmune diseases. 
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Although the molecular mechanism explaining how the C4BP induce tolerogenicity in 
pro-inflammatory stimulated DCs is not yet known, other cellular types, also fundamental in 
the inflammatory mechanisms such as monocyte-derived macrophages, can present the same 
tolerogenic characteristics. To verify the therapeutic efficiency of C4BP (β-) in vitro studies 
analogous to those performed with DCs, and in vivo studies in animal models with 
inflammatory alterations like NZB/W F1 mice that express spontaneous SLE are essential. 
This work is based in in vitro experiments with the objective of understanding if the C4BP 
isoforms modify the inflammatory activity of monocyte-derived macrophages polarized to M1 
and M2. To achieve this goal, phenotype characteristics of macrophages were analyzed. For 
GM-CSF-differentiated macrophages polarized to M1, the surface markers CD64 and CD80 
were analyzed, and for M-CSF-differentiated macrophages polarized to M2. the surface 
markers CD209 and CD11b were used. The effect of C4BP (β-) on the endocytic and phagocytic 
activity of M1 and M2 polarized macrophages was also evaluated. 
The structural requirements for the functional activities of C4BP are also of interest, 
because C4BP is the major regulator of the classical pathway of complement, and it may have 
therapeutic potential. Subsequently, the final goal of this research was to assess the 
consequences of C4BP (β-)-mediated induction of the phenotype and functional behavior of 
pro-inflammatory (M1) or anti-inflammatory, pro-resolving (M2) conditions of monocyte-
derived macrophages. 
 
 
Document Structure 
 
This thesis is organized into five major chapters, each one related to a specific part of the 
research. The remainder of this section presents a brief theoretical introduction to a better 
understanding, the main motivations, and objectives of this project. 
Chapter 2 starts by presenting each of the most relevant techniques and the respective 
materials used in the process. 
The obtained results are found in Chapter 3 and the respective discussion in Chapter 4. 
Finally, conclusions and some insight on future work and research are provided in 
Chapter 5. 
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Chapter 2 
Materials and Methods 
 
2.1. Monocyte isolation from peripheral blood  
 
The studies were performed using human monocyte-derived macrophages (MDMs), from 
PMBCs. These were obtained from buffy coat preparations collected from healthy blood donors 
from the Blood and Tissues Bank (Barcelona, Spain) and isolated by density gradient 
centrifugation. 
Therefore, 30mL of total blood were placed in 50mL Falcon tubes and centrifuged for 20 
min at 1500xg and room temperature (Heareus Multifuge 3 LR, Thermo Scientific, USA). The 
resulting gradient divided the blood sample into the following phases, according to the cells 
density: RBCs, WBCs + platelets, and plasma. With a pipette, the leukocytes and platelets were 
placed in new 50mL Falcon tubes and the volume was increased up to 50mL with PBS (DPBS 
w/o Calcium and w/o Magnesium, Pan Biotech, Germany). Next, 15mL of Ficoll (Ficoll-Paque, 
GE Healthcare Bio-Sciences AB, Uppsala, Sweden) were added to 50mL Falcon tubes and 
25mL of the previous diluted cells with PBS were added carefully on the top of the tubes with 
Ficoll and centrifuged for 25 min at 400xg and room temperature. After density gradient 
separation, a white layer could be easily observed, which corresponds to the PMBCs. These 
cells were carefully collected with a Pasteur pipette to new 50mL Falcon tubes and washed with 
PBS to clean the cells. Two additional centrifugations of 10 min at 400xg and room temperature 
were performed, the supernatant was removed and, finally, the cells were diluted in PBS to a 
final volume of 10mL. 
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2.2. Cellular count by flow cytometry 
 
The isolated cells were counted by flow cytometry to estimate the necessary volume to 
be used in the experiment. For functional assays, 40µL of PBS, 20µL of PMBCs and 4µL of 
monoclonal mouse anti-human CD14 antibody (MACS Miltenyi Biotec, Germany) were placed 
in a cytometry tube. After 15 min, 120µL of PBS were added to stop the reaction and 
supplemented with 5µL of 7-Aminoactinomicin D (7-AAD) (7-AAD, Viability Staining 
Solution, eBioscience) to differentiate alive and dead cells, yielding the percentage of cellular 
viability, and the tubes were incubated in the darkness during 5 min. After the incubation time, 
monocytes were purified and counted using 20µL of CD14+ magnetic microbeads (Perfect 
Count Microspheres, Cytognos SL, Salamanca, Spain). The purity of CD14+ cells was tested 
by CD14 staining and flow cytometry analysis (Cytometry FACScalibur, BD Biosciences), 
allowing the assessment of the number of PMBCs and the number of total CD14+(> 90% CD14+ 
cells). 
 
2.3. Monocyte-derived macrophage differentiation and polarization 
 
Monocytes were cultured at 1×106 cells/mL in a 24 well plate (24-well Tissue Culture 
Plate, Biofil) in RPMI 1640 medium, supplemented with 100 IU/mL penicillin, 100 µg/mL 
streptomycin and 2mM L-glutamine without serum (basal medium), and allowed to adhere for 
90 min at 37ºC in 5% of CO2. After 90 min, the nonadherent cells were removed by washing 
with PBS. Each well was filled with 800µL of RPMI 1640 medium, supplemented with 100 
IU/mL penicillin, 100 µg/mL streptomycin, 2mM L-glutamine (all from Invitrogen, Carlsbad, 
USA) and 10% heat-inactivated FBS (Linus, Cultek, Spain) (complete medium). The wells 
were also supplemented GM-CSF to those containing monocytes that would subsequently be 
polarized to M1, or with M-CSF to those containing monocytes that would subsequently be 
polarized to M2. The factor under study, the C4BP (β-) or C4BP α7β0 was added to the 
corresponding wells with a concentration of 10µg/Ml, and a control of each condition (M0 and 
M0+β- with GM-CSF and M-CSF) was made (Figure 4). The macrophage differentiation lasts 
6 days at 37ºC in 5% of CO2, and a change of medium is performed at day 4 (Figure 5). 
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Figure 4. Disposition of a 24 wells plate for the in vitro macrophages differentiation and polarization, and 
assessment of the C4BP (β-) effect. Monocyte-derived macrophages were polarized to M1 and M2 in the presence 
of GM-CSF and M-CSF, respectively. The protein under study, the C4BP β- isoform was added to the 
corresponding wells. M0 and M0+β- corresponds to the controls, also cultivated with GM-CSF or M-CSF. The 
PBS was added to the surrounding wells to prevent the evaporation of the medium on the cells. 
 
After 6 days, the supernatants were aspired and the cells were resuspended in 500µL of 
complete medium with GM-CSF and M-CSF, according to the corresponding wells. 
Uncommitted macrophages (M0) were polarized into M1 using E. coli LPS (40ng/mL) (Sigma, 
USA) plus rhIFN-γ (40ng/mL) (Invitrogen, USA) and into M2 using rhIL-4 alone (40ng/mL) 
(Invitrogen, USA) for 2 days (Figure 5). The C4BP (β-) (α7β0) was added to the corresponding 
wells at a concentration of 10µg/mL. Macrophages from different donors were polarized in 
independent experiments. 
          
 
Figure 5. Human monocytes were differentiated into uncommitted macrophages (M0) by granulocyte macrophage 
colony-stimulating factor (GM-CSF) or macrophage colony-stimulating factor (M-CSF). After 6 days of 
incubation at 37ºC in 5% of CO2, macrophages were polarized into classically activated (M1) or alternatively 
activated (M2) using LPS/IFN-γ or IL-4, respectively, for 2 more days. After 8 days from the beginning of the 
experiment, the phenotype was analyzed by flow cytometry. 
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2.4. Flow cytometry 
 
On day 8, the macrophages were recovered from the wells to 15mL Falcon tubes, 
centrifuged 10 min at 400xg and room temperature, washed with PBS. The supernatant was 
preserved at -80ºC on Eppendorf tubes for future immunoassays. The adhered cells were 
removed by carefully knocking on the plate, pipetting and scrapping. Once the wells were clean, 
visible on the microscopy, the Falcon tubes were centrifuged for 10 min at 400xg and room 
temperature. Finally, the supernatant was aspired and the pellet was used for flow cytometry 
analysis. 
 
2.4.1. Surface marker analysis  
 
To examine the macrophage surface markers, the pellet was resuspended in 20µL of PBS 
and added to the cytometry tube with 60µL of PBS, 3µL of CD64-APC and 3µL of CD80-PE, 
in the case of M1 polarized macrophages, or 60µL of PBS, 3µL of CD209-APC and 3µL of 
CD11b-PE in the case of M2 polarized macrophages. After 15 min of incubation at room 
temperature, the reaction was stopped with 120µL of PBS and 2,5µL of 7-AAD, and flow 
cytometry analysis (Cytometry FACSCanto II, Becton Dicknson) was performed to assess the 
viability and phenotype of the cells.  
 
2.4.2. Endocytosis analysis using OVA and LY 
 
Another cytometry study was performed to investigate the different types of macrophage 
endocytosis. When macrophages take up and process Ovalbumin (OVA) captured by receptor-
mediated endocytosis, and Lucifer Yellow CH (LY) captured by pinocytosis, the cells exhibit 
a characteristic shift or gain in fluorescence intensity. For this purpose, OVA (Stock 1mg/mL) 
was diluted in PBS, and 4µL were added to cytometry tubes containing 60µL of RPMI complete 
medium and 20µL of cells. To demonstrate intracellular uptake, loading was performed at 4°C 
and at 37°C for 1 h, because intracellular uptake is energy-dependent. After 1 h, the reaction 
was stopped with 150µL of FACS buffer (PBS + 1% BSA + 0,1% NaN3), 2,5µL of 7-AAD and 
flow cytometry analysis (Cytometry FACSCanto II, Becton Dicknson) was performed to assess 
the viability and endocytosis status of the cells. 
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LY (Stock 10mg/mL) was diluted in H2O and 6µL were added to cytometry tubes 
containing 60µL of RPMI complete medium. The same protocol than the OVA uptake was 
employed, but the incubation time was 2,5 h instead of 1 h. Then, the reaction was stopped with 
150µL of FACS buffer and 2 additional washes were performed. The washes consisted of 
transferring the mixture to Eppendorf tubes, centrifuging them at maximum speed for 3 min, 
removing supernatant and adding 150µL more of FACS buffer. Finally, the mixture was 
returned to the cytometry tubes, 2,5µL of 7-AAD were added and the suspension was analyzed 
by flow cytometry (Cytometry FACSCanto II, Becton Dicknson). 
 
2.4.3. Phagocytosis analysis 
 
Phagocytosis was studied using pHrodo™ Green E. coli BioParticles (Stock 0,909 
mg/mL) diluted in 2.2mL of PBS. For each condition, 100µL of PBS and 20µL of the diluted 
E. coli BioParticles were added, and one of the plates was placed at 4°C and another at 37°C 
for 1 h. After the incubation time, 130µL of PBS was added making a total of 250µL. The 
adherent macrophages were removed by scrapping and pipetting. Once removed, the 250µL 
suspension was collected on a cytometry tube, 2,5µL of 7-AAD were added and flow cytometry 
analysis was performed (Cytometry FACSCanto II, Becton Dicknson). 
 
2.5. Statistical analysis  
 
All flow cytometry data were analyzed using the FlowJo software (Miltenyi Biotec). 
Statistical analysis was performed using GraphPad Prism software (GraphPad Prism version 
xxxx for Windows, GraphPad Software, La Jolla California USA) and data were expressed 
as the mean ± SD. A P value of less than 0.05 was considered to be statistically significant. 
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Chapter 3 
Results 
  
3.1. Human monocyte-derived macrophage morphology  
 
Collected from the human peripheral blood, monocytes were differentiated into 
unstimulated macrophages (M0) by growth factors such as granulocyte-macrophage colony 
stimulation factor (GM-CSF) and macrophage stimulating factor (M-CSF). M0 macrophages 
were polarized to M1 and M2 phenotypes. 
When stimulated in culture with cytokines to induce M1 and M2 polarization, the 
macrophages displayed markedly different morphologies. Addition of LPS and IFN-γ, which 
stimulate M1 polarization, caused cells to flatten into a round, pancake-like shape within 48h 
of stimulation (Figure 6-A). In contrast, the addition of IL-4, which stimulates M2 
differentiation, led to cellular elongation (Figure 6-B). 
 These results prove that phenotypic polarization of macrophages is regulated by the local 
tissue microenvironment and showing that M2 cells exhibited a significantly higher degree of 
elongation compared with either M1 or unstimulated M0 cells. 
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Figure 6. Characterization of macrophages morphology after M1 or M2 polarization. (A) After stimulation with 
LPS/IFN-γ, M1 macrophages showed a rounded morphology. (B) M2 macrophages stimulated with IL4 adopted 
an elongated cell morphology. 
 
 
 
3.2. Human monocyte-derived macrophage treatment with C4BP (β-) 
 
3.2.1. C4BP (β-) affects the polarization phenotype of human macrophages 
 
The expression of a panel of surface molecules on macrophages was analyzed by flow 
cytometry after 2 days of in vitro polarization of human blood monocytes with IFN-γ/LPS and 
IL-4, using unpolarized cells (M0 and M0+ β-) as a control.  
Macrophages activated with IFN-γ and LPS (M1 phenotype) displayed a robust and 
specific upregulation of the co-stimulatory molecule CD80 and a downregulation of the CD64 
receptor, as compared to the unpolarized cells (Figure 7). The macrophages activated via IL-4 
(M2 phenotype) displayed a highly upregulated expression of the myeloid cell markers CD11b 
and CD209, compared with the control cells (Figure 8).  
In summary, these data indicate that human macrophages polarized to M1 with IFN-γ and 
LPS specifically express CD80 and CD64, and human macrophages polarized to M2 with IL-4 
upregulate CD11b and CD209, confirming that the candidate markers were robustly and 
reproducibly modulated by the polarizing factors and proving their specificity for each type of 
activated macrophages.  
A B 
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When the macrophages were treated with the protein under study, C4BP (β-) or C4BP 
α7β0 isoform, a decrease of CD64 and CD80 expression was visible in M1 macrophages (Figure 
7), and a reduction of CD11b and CD209 expression was observed in M2 macrophages (Figure 
8). 
 
Figure 7. Relative mean fluorescent intensity (MFI) for M1 macrophage surface markers and effect of C4BP(β-). 
Monocyte-derived macrophages polarized with IFN-γ and LPS, presenting a M1 phenotype, express an regulation 
of CD80 and CD64.When analyzed by flow cytometry for surface marker expression, CD80-PE and CD64-APC 
antibodies allow the visualization of an increase (CD80) or decrease (CD64) in M1, compared with the control 
(M0). When exposed to the C4BP(β-) isoform, a significant prevention of CD80 and CD64 overexpression occurs, 
similar to the control M0 + β-. The results shown are the mean ± SD from five independent experiments. **p < 
0.01, ***p < 0.001, ****p < 0.0001, compared to M1. 
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3.2.2. C4BP (β-) affects the endocytosis of human macrophages 
 
The endocytic capacity on macrophages was analyzed after 2 days of in vitro polarization 
of human blood monocytes with IFN-γ and LPS for the M1 phenotype, and IL-4 for the M2 
phenotype, using unpolarized cells (M0 and M0+ β-) as a control. When macrophages take up 
Ovalbumin (OVA) captured by receptor-mediated endocytosis (Figure 9), and Lucifer Yellow 
CH (LY) captured by pinocytosis (Figure 10), exhibit a characteristic shift in fluorescence 
intensity captured by flow cytometry. 
When the macrophages were classically activated (M1 phenotype), a downregulation of 
their endocytic activity in relation to the control M0 was observed, either in macrophages 
treated with OVA or with LY (Figures 9-A and 10-A). In contrast, when the macrophages 
were alternatively activated (M2 phenotype), M2 polarization did not change or slightly 
increased their endocytic activity, compared to the control M0 (Figures 9-B and 10-B).  
CD209-APC N=6 
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F
I 
CD11b-PE N=7 
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F
I 
Figure 8. Relative mean fluorescent intensity (MFI) for M2 macrophage surface markers. Monocyte-derived 
macrophages polarized withIL-4, presenting a M2 phenotype, express an upregulation of CD11b and CD209.When 
analyzed by flow cytometry for surface marker expression, CD11b-PE and CD209-APC antibodies allow the 
visualization of an increase in M2, compared with the control (M0). When exposed to the C4BP(β-) isoform, a 
significant prevention of CD11b and CD209 overexpression occurs, approaching to the control M0 + β-.  The 
results shown are the mean ± SD from six to seven independent experiments. ***p < 0.001, ****p < 0.0001, 
compared to M2. 
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When the classically and alternatively polarized macrophages were treated with the C4BP 
(β-) isoform, a decrease of fluorescence occurred, showing a downregulation of the endocytic 
activity in both M1 and M2 macrophages, and also in non-polarized cells.  
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Figure 9. Representation of the endocytic activity of (A) M1 and (B) M2 polarized macrophages when Ovalbumin 
(OVA) is captured by receptor-mediated endocytosis. (A) When the macrophages are classically polarized (M1), 
a downregulation of the endocytic activity occurs. (B) An upregulation of the endocytic activity is also visible 
when macrophages are alternatively activated (M2). In both cases, the C4BP (β-) downregulates endocytosis. 
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3.2.3. C4BP (β-) does not affect the phagocytosis of human macrophages 
 
The phagocytic capacity of macrophages was studied after 2 days of in vitro polarization 
of human macrophages derived from blood monocytes, with IFN-γ and LPS for the M1 
phenotype and IL-4 for the M2 phenotype, using unpolarized cells (M0 and M0+ β-) as a 
control. When macrophages captured pHrodo™ Green E. coli BioParticles by phagocytosis, a 
characteristic shift in fluorescence intensity was evident by flow cytometry, allowing 
quantification of the phagocytic activity. 
When macrophages were polarized to the M1 phenotype no difference in the phagocytic 
activity of macrophages was observed respect to unpolarized macrophages (M0). In contrast, 
when these cells were polarized into M2 phenotype, an upregulation of the phagocytic activity 
was detected relative to the control unpolarized cells (M0) (Figure 11).  
When the C4BP (β-) was applied on both unpolarized and polarized (M1 and M2) 
macrophages, no significant difference in the phagocytic activity was observed respect to 
untreated cells. 
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Figure 10. Representation of the endocytic activity of (A) M1 and (B) M2 polarized macrophages when Lucifer 
Yellow (LY) is captured by pinocytosis. (A) When the macrophages are classically polarized (M1), a 
downregulation of the endocytic activity occurs. (B) An upregulation of the endocytic activity is also visible when 
macrophages are alternatively activated (M2). In both phenotypes, the C4BP (β-) downregulates endocytosis. 
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In resume, while M-CSF-differentiated macrophages displayed increased phagocytosis 
compared with GM-CSF-differentiated macrophages, either M1/M2 polarization or C4BP (β-) 
treatment did not have any influence in phagocytosis activity (Figure 11). 
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Figure 11. Representation of the phagocytic activity of M1 and M2 polarized macrophages when pHrodo™ 
Green E. coli BioParticles is captured by phagocytosis. M2 polarized macrophages displayed an increase of 
phagocytic activity compared to M1 polarized macrophages. C4BP (β-) treatment did not have any influence in 
phagocytosis activity. 
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Chapter 4 
Discussion 
 
4.1. Human monocyte-derived macrophages morphology  
 
Macrophages are key regulators of the immune response during infection and wound 
healing, being the first cells sensing pathogens or damage. Their behavior is induced by soluble 
factors in the local microenvironment, which is critical for regulating the proinflammatory or 
healing state of these cells.  
To fulfill their functionally distinct roles, macrophages are capable of polarizing toward 
a spectrum of phenotypes, which include classical pro-inflammatory activation (M1), and 
alternative activation (M2), is responsible for wound healing and tissue repair. In the presence 
of inflammatory stimuli and danger signals, macrophages polarize to M1 phenotype and release 
inflammatory cytokines to fight pathogens. In contrast, a wound healing environment promotes 
polarization toward an M2 phenotype and leads to cellular processes that facilitate tissue repair.  
We observed that monocyte-derived macrophages stimulated in culture with cytokines to 
induce M1 or M2 polarization displayed markedly different cell morphologies (Figure 6). He 
addition of GM-CSF, LPS and IFN-γ, which stimulate M1 polarization, caused cells to flatten 
into a round, pancake-like shape within 48h of stimulation (Figure 6-A). On the other hand, 
the addition of M-CSF and IL-4, which stimulate M2 polarization, led to cellular elongation 
(Figure 6-B), suggesting an important role for cell shape involving macrophage function. 
 
 
4.2. Human monocyte-derived macrophage treatment with C4BP (β-) 
 
The complement system constitutes a key arm of the innate immune response in the fight 
against pathogen infection. To maintain immune homeostasis, the main fluid-phase 
complement inhibitor C4BP presents complementary activities in the regulation of excessive 
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complement activation and offer protection against its deleterious consequences into the host 
by modulating inflammation and the development of adaptive immune responses. 
Previous studies in the lab identified the immunomodulatory capacity of the minor 
isoform of the protein C4BP (β-), in monocyte-derived dendritic cells. Nevertheless, this C4BP 
(β-) feature was not tested on monocyte-derived macrophages. Thus, a first step establishing a 
phenotypic characterization of M1 and M2 macrophages and understand their endocytosis 
activity under C4BP (β-) influence is fundamental to recognize its function and activity in 
different diseases. 
Moreover, we also established a phenotypic and endocytic characterization of matured 
macrophages to M1 and M2 and the effect of the immunomodulator C4BP (β-) on these mature 
cells. Furthermore, considering the physiological activity of C4BP as soluble complement 
modulator, its interaction with monocytes and macrophages was nontoxic, and the 
corresponding macrophages maintained the same viability through the differentiation and 
maturation stages.  
 
4.2.1. C4BP (β-) affects the polarization phenotype of human macrophages 
 
Previous studies on human macrophages were particularly focused on the differential 
gene expression profiles of M1 and M2 macrophages as well as on identification of functional 
surface markers. However, a clear phenotypic characterization of human M1 and M2 subsets is 
important for better understanding of their biological functions and their roles in diseases. 
As referred before, the macrophage behavior is regulated by soluble growth factors in the 
local microenvironment that allows the polarization of these cells to M1 or M2 phenotype, 
showing that they are critical for regulating the proinflammatory or healing state of these cells. 
When GM-CSF-differentiated macrophages were polarized to M1 by LPS and IFN-γ, resulting 
in a macrophage surface expression pattern characterized by an increase of the maturation 
markers CD80 and CD64 (Figure 5). M-CSF-differentiated M2 macrophages polarized by IL-
4 could be best described by surface expression of CD11b and CD209 (Figure 6).  
As shown in the results section, macrophages responded to stimuli and are highly 
sensitive to culture conditions. M1 and M2 macrophages express an increase of CD80-CD64 
and CD11b-CD209 surface markers, respectively, compared with the unpolarized macrophages 
   
 
33 
 
(M0), which means that the validation of specific phenotypic markers is highly relevant for 
further investigation of different aspects of human macrophage biology. 
 When the C4BP (β-) was added previously to M1 and M2 macrophages polarization, the 
expression of the maturation markers CD80 and CD64 for the proinflammatory macrophages 
(Figure 5) and the CD11b and CD209 for the anti-inflammatory macrophages (Figure 6) 
experienced a substantial decrease, showing similar levels than unpolarized cells (M0). This 
results demonstrated that the α7β0 isoform of C4BP was able to directly modulate the biological 
behavior of monocyte-derived macrophages preventing their polarization. 
 
4.2.2. C4BP (β-) affects the endocytosis capacity of human macrophages 
 
Macrophage cells patrol around the tissue where they reside and play a central role in the 
clearance of pathogens. Endocytosis and phagocytosis represent mechanisms by which M1 and 
M2 macrophages eliminate and engulf, correspondingly, these foreign pathogens, maintaining 
immune homeostasis. 
The macrophage endocytic capacity was analyzed after 2 days of in vitro polarization 
through uptake of Ovalbumin (OVA) protein by receptor-mediated endocytosis, and of Lucifer 
Yellow CH (LY) by pinocytosis. These present fluorescent properties that could be observed 
by flow cytometry.  
Receptor-mediated endocytosis provides a mechanism for the selective uptake of specific 
macromolecules, such ovalbumin. To be internalized, OVA first binds to specific cell surface 
receptors. These receptors are concentrated in specialized regions of the plasma membrane, 
called clathrin-coated pits. These pits migrate from the membrane to form small clathrin-coated 
vesicles containing the receptors and the bounded OVA. In contrast, pinocytosis is also known 
as “cell drinking” or ingestion of fluids, like LY. In this type of endocytosis, much smaller 
vesicles are formed compared to receptor-mediated endocytosis, since it only ingests liquid 
substances. After macrophages engulf the pathogen, an invagination occurs to form a vacuole 
called phagosome, that is formed inside the cell. 
When macrophages were matured to M1 phenotype, a decrease of the endocytic activity 
in both macrophages treated with OVA (Figure 8-A) and LY (Figure 9-A) was observed, 
compared to the unpolarized cells (M0). The opposite occurred when macrophages were 
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polarized to M2 phenotype, since an overexpression of endocytic activity in both OVA (Figure 
8-B) and LY (Figure 9-B) treated macrophages was evident, compared with M0. 
When C4BP (β-) was added to M1 and M2 macrophages, a substantial downregulation of 
the endocytic capacity comparing to the M1 and M2 controls was evident, showing that C4BP 
(β-) treatment reduced the high endocytic activity characteristic of monocyte-derived 
macrophages.  
 
4.2.3. C4BP (β-) does not affect phagocytosis on human macrophages 
 
In mammals, phagocytes are polymorphonuclear leukocytes and monocytes/ 
macrophages. The first phase of the process is the recognition of particles by the cell, which is 
a physicochemical interaction between components of the cell membrane and the particle, 
leading to attachment of the particle, and is followed by the internalization into vacuoles.  
As referred before, phagocytosis is one the principal characteristics of macrophage cells, 
representing one of the mechanisms by which M1 and M2 matured macrophages engulf invader 
microorganisms, maintaining immunological homeostasis. 
When the mature macrophages captured, by phagocytosis, pHrodo™ Green E. coli 
BioParticles the phagocytic activity of these cells was evident. On the other hand, polarized 
macrophages into M2 phenotype present an upregulation of the phagocytic activity in relation 
to the control unpolarized control (M0) (Figure 11). These results demonstrated a higher 
phagocytic capacity of alternatively polarized macrophages. 
When the C4BP (β-) was added on the M1 and M2 activated macrophages, there was not 
a significant difference in the phagocytic activity in both types of macrophages, compared with 
their controls (GM-CSF-treated M1 and M-CSF-treated M2, respectively). However, more 
experiments are needed to obtain a better evaluation of these results. 
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Chapter 5 
Conclusions 
 
Macrophages play critical roles in the body's defense system by eliminating 
microorganisms from infected tissues and also aged or dead cells from tissues throughout the 
body. In vitro conditions for differentiating human monocytes into macrophages and then 
polarizing them into M1 and M2 subsets were defined. These results provide a way to 
characterize human M1 and M2 macrophages, which will aid the study of human macrophage 
biology and in the analysis of macrophage profile in clinical samples. 
In this study, it was observed that C4BP (β-) is capable of preventing the polarization to 
M1 and M2, and retain to an unpolarized (M0) phenotype without loss of viability. These results 
were characterized for a downregulation of expression macrophage surface markers in M1, such 
as CD80 and CD64, and in M2, such as CD11b and CD209. 
Thanks to the endocytosis (OVA) and pinocytosis (LY) assays on monocyte-derived 
macrophages the immunomodulatory capacity of C4BP (β-), unrelated to complement 
regulation was confirmed. This protein is able to downregulate the endocytic activity and, 
consequently, the antigen presentation ability of macrophages. The C4BP (β-) isoform was able 
to directly modulate the biological behavior of monocytes-derived macrophages, influencing 
both innate and adaptive immunity by directly inducing a semi mature, anti-inflammatory and 
tolerogenic phenotype on these cells. 
Phagocytosis experiments on monocyte-derived macrophages shown a higher phagocytic 
capacity on M2 polarized cells compared with M1 and unpolarized cells. Moreover, C4BP (β-) 
had no influence on the phagocytic activity, although additional experiments are needed to 
confirm this point. 
Taken together, the macrophage subset characterization can be used to investigate 
macrophage-related disease pathogenesis, facilitating the development of therapeutic 
interventions, where modulating the function of macrophage subsets could be beneficial for 
patients. Also, C4BP (β-)-mediated exposure to monocyte-derived macrophages might have 
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therapeutic potential as an anti-inflammatory and immunomodulatory agent in immune-
inflammatory pathologies, such as hypersensitivity, transplantation, and autoimmunity. 
 
5.1. Future work 
 
Future challenges include the identification of the putative C4BP (β-) surface receptor 
responsible for the immunomodulatory activity and the determination of full molecular 
mechanism involved in C4BP (β-)-induced macrophage transformation to a tolerogenic state. 
Finally, the physiological relevance of this C4BP (β-)-mediated immunomodulatory activity 
and therapeutic efficacy of C4BP (β-) administration to appropriate animal models of 
inflammation. 
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